Contact
Please use this form to send email to PR contact of this press release:
Merck Announces Settlement and License Agreement Resolving KEYTRUDA® (pembrolizumab) Patent Litigation
TO:
Please use this form to send email to PR contact of this press release:
Merck Announces Settlement and License Agreement Resolving KEYTRUDA® (pembrolizumab) Patent Litigation
TO: